GRI Bio
$2.88
54
+$0.59+25.76% Friday 20:00
-$0.30-10.28%Friday 23:59After hours
Statistics
Day High
2.9
Day Low
2.87
52W High
80.36
52W Low
1.36
Volume
27,396
Avg. Volume
-
Mkt Cap
6.3M
P/E Ratio
0.04
Dividend Yield
-
Dividend
-
Upcoming
Earnings
18NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-35.84
-24.2
-12.55
-0.91
Expected EPS
-0.93
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-11.96MNet Income
Analyst Ratings
32.00Average Price Target
The highest estimate is 32.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow GRI. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap236.38B
Gilead Sciences
GILD
Mkt Cap187.23B
Biogen
BIIB
Mkt Cap32.63B
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Moderna
MRNA
Mkt Cap58.11B
Alnylam Pharmaceuticals
ALNY
Mkt Cap35.61B
Biomarin Pharmaceutical
BMRN
Mkt Cap12.88B
Novartis
NVS
Mkt Cap304.1B
Holdings
Regions
Sectors
About
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Show more...
CEO
W. Marc Hertz
Employees
5
Country
United States
ISIN
US3622AW5029
Listings
0 Comments
Share your thoughts
FAQ
What is GRI Bio stock price today?▼
The current price of GRI is $2.88 USD — it has increased by +25.76% in the past 24 hours. Watch GRI Bio stock price performance more closely on the chart.
What is GRI Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange GRI Bio stocks are traded under the ticker GRI.
Is GRI Bio stock price growing?▼
GRI stock has risen by +50.79% compared to the previous week, the month change is a +95.92% rise, over the last year GRI Bio has showed a -93.41% decrease.
What is GRI Bio market cap?▼
Today GRI Bio has the market capitalization of 6.3M
When is the next GRI Bio earnings date?▼
GRI Bio is going to release the next earnings report on November 18, 2026.
What were GRI Bio earnings last quarter?▼
GRI earnings for the last quarter are -0.91 USD per share, whereas the estimation was -1.2 USD resulting in a +23.85% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is GRI Bio revenue for the last year?▼
GRI Bio revenue for the last year amounts to 0 USD.
What is GRI Bio net income for the last year?▼
GRI net income for the last year is -11.96M USD.
How many employees does GRI Bio have?▼
As of September 08, 2026, the company has 5 employees.
In which sector is GRI Bio located?▼
GRI Bio operates in the Health & Wellness sector.
When did GRI Bio complete a stock split?▼
The last stock split for GRI Bio was on January 26, 2026 with a ratio of 1:28.
Where is GRI Bio headquartered?▼
GRI Bio is headquartered in LA JOLLA, United States.